“…We present an updated analysis of all clinically relevant outcomes (nonfatal MI, renal events, changes in systolic blood pressure from baseline, CHF, stroke, and death) presented in clinical trials and older metaanalyses. 22,23 Our results confirm those of Kumbhani et al 22 and Pierdomenico et al 23 who suggested that PTRA and PTRAS are not superior to medical therapy alone with respect to all-cause mortality, nonfatal MI, and stroke. Our results contrast those of a recent individual patient meta-analysis, which showed that systolic blood pressure and diastolic blood pressure were significantly lower at 9 months after renal artery stent revascularization.…”